Scholars Central

Research articlePublished 2014

New chemical entities of future for infectious diseases

Authors: Abida, Mohd. Imran, Mohamed A. M. Hagga, Said A. El-Feky

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A number of infectious disease treatments are available today. However, infectious diseases still pose serious threats to patients because of the development of antibiotic resistance and the emergence of new infectious diseases. As on date, about 400 drugsincluding New Chemical Entities (NCEs), biologics, vaccines, new dosage forms and drug combinations areat different phases of their development (pre-clinical, Phase I, Phase II, Phase III or preregistration phase) against infectious diseases. This article provides preliminary information about New Chemical Entities (NCEs) for which New Drug Application (NDA) has been submitted by pharmaceutical companies to Food and Drug Administration (FDA) or which are in Phase III of their clinical trial. It would be interesting to see how many of New Chemical Entities (NCEs), among those discussed in this article, will see the face of the future.

Subjects

Biology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in European Journal of Experimental Biology.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalEuropean Journal of Experimental Biology
  • SubjectBiology
  • BylineArticles whose byline prints “Abida”
  • BylineArticles whose byline prints “Mohd. Imran”
  • BylineArticles whose byline prints “Mohamed A. M. Hagga”
  • BylineArticles whose byline prints “Said A. El-Feky”